Eli Lilly, a U.S. pharmaceutical company, has enlisted Swiss contract drugmaker CordenPharma to produce the active ingredient, tirzepatide, for its diabetes drug Mounjaro. This development coincides with Lilly’s preparations to launch Mounjaro as a treatment for weight loss in the United States, driven by increasing demand for obesity medications. Although Mounjaro has not yet received official U.S. approval for weight loss, doctors are already prescribing it “off-label” to patients seeking to lose weight. CordenPharma’s Colorado facility is under a confidential contract to manufacture tirzepatide for the weekly injection. This partnership reflects the growing market for weight-loss drugs, providing a significant boost to contract development and manufacturing organisations (CDMOs) like CordenPharma, which have been offsetting COVID-19-related contract losses.
Where Industry Meet Trends
Menu
English